Equity Vii L.P. Spectrum Sells 23,771 Shares of GoodRx (NASDAQ:GDRX) Stock

Key Points

• Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock on October 15th for a total value of $95,084, as disclosed in a legal filing with the SEC.
• GoodRx reported a missed earnings estimate for the last quarter, posting $0.09 earnings per share compared to the consensus estimate of $0.10.
• Analysts have a consensus rating of "Hold" for GoodRx, with a price target averaging around $5.80.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the firm's stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Equity Vii L.P. Spectrum also recently made the following trade(s):

• On Friday, September 5th, Equity Vii L.P. Spectrum sold 16,016 shares of GoodRx stock. The shares were sold at an average price of $4.05, for a total value of $64,864.80.

GoodRx Stock Performance

GoodRx stock traded down $0.12 during mid-day trading on Thursday, reaching $3.90. 3,405,892 shares of the stock traded hands, compared to its average volume of 2,444,802. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a 12-month low of $3.31 and a 12-month high of $6.97. The stock has a market capitalization of $1.36 billion, a PE ratio of 39.00, a price-to-earnings-growth ratio of 1.80 and a beta of 1.23. The business's 50-day moving average is $4.20 and its 200-day moving average is $4.37.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The business had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same quarter in the previous year, the business posted $0.08 earnings per share. The firm's revenue was up 1.2% on a year-over-year basis. As a group, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on GDRX shares. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of GoodRx in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $5.80.

Institutional Trading of GoodRx

Several large investors have recently made changes to their positions in GDRX. 8 Knots Management LLC purchased a new stake in shares of GoodRx in the 1st quarter valued at $8,106,000. EVR Research LP boosted its holdings in shares of GoodRx by 243.3% in the 1st quarter. EVR Research LP now owns 1,300,000 shares of the company's stock valued at $5,733,000 after acquiring an additional 921,337 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in shares of GoodRx in the 3rd quarter valued at $3,687,000. Pathway Capital Management LP purchased a new stake in shares of GoodRx in the 2nd quarter valued at $2,906,000. Finally, Jane Street Group LLC boosted its holdings in shares of GoodRx by 481.5% in the 2nd quarter. Jane Street Group LLC now owns 487,887 shares of the company's stock valued at $2,430,000 after acquiring an additional 403,981 shares during the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.